Tag: commercial

MONTRÉAL, June 26, 2026 (GLOBE NEWSWIRE) -- Rogers Sugar Inc. (the “Company” or “Rogers Sugar”) (TSX: RSI) today announced that the ‘’United Food and Commercial Workers Union’’ representing the employees at its Taber sugar beet refinery has ratified the extension of its current collective agreement to March 2032.

LOS ANGELES, June 26, 2026 (GLOBE NEWSWIRE) -- XMax Inc. (Nasdaq: XMAX) ("XMax" or the "Company") today announced a significant commercial milestone in its artificial intelligence business, reporting that since launching its AI platform initiative, the Company has executed multiple AI model API service agreements with an aggregate contractual value of up to approximately US$25 million, subject to actual service usage and consumption levels.

LIKMEZ® (ATI-1501) commercial momentum building in U.S. market

US$40 million NIAID award supporting VXV-01 advancement through Phase 1

MONTRÉAL, June 26, 2026 (GLOBE NEWSWIRE) -- Rogers Sugar Inc. (the “Company” or “Rogers Sugar”) (TSX: RSI) today announced that the ‘’United Food and Commercial Workers Union’’ representing the employees at its Taber sugar beet refinery has ratified the extension of its current collective agreement to March 2032.

Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination

BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host an investor event to discuss updates for the Company’s nomlabofusp clinical development program including a regulatory update and data from the ongoing long-term open label study for the treatment of Friedreich’s ataxia on Monday, June 29, 2026 at 7:45 am ET.

Ji'an, Jiangxi, China, June 26, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China, today announced that the Company has entered into a share purchase agreement to acquire 100% of the issued shares of Best Praise International Limited (“Best Praise”), a company that holds five patents in China with potential applications in pharmaceutical development, for a total purchase price of US$10,751,000, payable in the form of 4,376,552 Class A ordinary shares of the Company.